Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2018
At a glance
- Drugs Ambrisentan (Primary)
- Indications Congenital heart defects
- Focus Pharmacokinetics
- 14 Nov 2018 Results developing a population PK model by taking data from this trial, presented at the 91st Annual Scientific Sessions of the American Heart Association.
- 31 Aug 2018 Biomarkers information updated
- 09 May 2018 Planned End Date changed from 1 Jun 2018 to 1 Jul 2019.